These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 25765457)
1. Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. Matsumoto K; Onda T; Yaegashi N Jpn J Clin Oncol; 2015 May; 45(5):408-10. PubMed ID: 25765457 [TBL] [Abstract][Full Text] [Related]
2. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer. Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263 [TBL] [Abstract][Full Text] [Related]
3. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Edwards SJ; Barton S; Thurgar E; Trevor N Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481 [TBL] [Abstract][Full Text] [Related]
4. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. Grisham RN; Iyer G; Sala E; Zhou Q; Iasonos A; DeLair D; Hyman DM; Aghajanian C Int J Gynecol Cancer; 2014 Jul; 24(6):1010-4. PubMed ID: 24978709 [TBL] [Abstract][Full Text] [Related]
6. Future directions in the chemotherapy of ovarian cancer. Ozols RF Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230 [TBL] [Abstract][Full Text] [Related]
8. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190 [TBL] [Abstract][Full Text] [Related]
9. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569 [TBL] [Abstract][Full Text] [Related]
10. Treatment of recurrent ovarian cancer. Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464 [TBL] [Abstract][Full Text] [Related]
11. The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer. Giuliani J; Bonetti A Int J Gynecol Cancer; 2017 Nov; 27(9):1872-1876. PubMed ID: 28976446 [TBL] [Abstract][Full Text] [Related]
12. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study). Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479 [TBL] [Abstract][Full Text] [Related]
13. Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Fuh KC; Secord AA; Bevis KS; Huh W; ElNaggar A; Blansit K; Previs R; Tillmanns T; Kapp DS; Chan JK Gynecol Oncol; 2015 Dec; 139(3):413-8. PubMed ID: 26144600 [TBL] [Abstract][Full Text] [Related]
14. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Liu JF; Tolaney SM; Birrer M; Fleming GF; Buss MK; Dahlberg SE; Lee H; Whalen C; Tyburski K; Winer E; Ivy P; Matulonis UA Eur J Cancer; 2013 Sep; 49(14):2972-8. PubMed ID: 23810467 [TBL] [Abstract][Full Text] [Related]
15. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Dhillon S BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884 [TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. Herzog TJ; Pignata S; Ghamande SA; Rubio MJ; Fujiwara K; Vulsteke C; Armstrong DK; Sehouli J; Coleman RL; Gabra H; Scambia G; Monk BJ; Arranz JA; Ushijima K; Hanna R; Zamagni C; Wenham RM; González-Martín A; Slomovitz B; Jia Y; Ramsay L; Tewari KS; Weil SC; Vergote IB Gynecol Oncol; 2023 Mar; 170():300-308. PubMed ID: 36758420 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of chemotherapy according to Brouillard-Saby F; Saint-Martin C; Ray-Coquard I; Gladieff L; Pomel C; Colombo PE; Classe JM; Chevrier M; Joly F; De la Motte Rouge T; Floquet A; Sabatier R; Barranger E; Costaz H; Leblanc E; Marchal F; Pautier P; Bosquet L; Rodrigues M Int J Gynecol Cancer; 2023 Apr; 33(4):577-584. PubMed ID: 36631150 [TBL] [Abstract][Full Text] [Related]
20. Developmental chemotherapy and management of recurrent ovarian cancer. Bookman MA J Clin Oncol; 2003 May; 21(10 Suppl):149s-167s. PubMed ID: 17633784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]